摘要
目的探讨奥沙利铂(L-OHP)联合卡培他滨治疗晚期直肠癌的临床疗效和安全性。方法选择86例晚期直肠癌患者,随机分为试验组和对照组,试验组给予L-OHP联合卡培他滨治疗,对照组给予奥沙利铂联合氟尿嘧啶和亚叶酸钙(FOLFOX4)方案治疗,观察比较两组的治疗效果和安全性。结果对照组和试验组治疗的有效率分别为51.2%和55.8%(P>0.05)。两组患者的主要不良反应有恶心呕吐、腹泻、白细胞减少、血小板减少、口腔黏膜炎、手足综合征和神经毒性,其中血小板减少、口腔黏膜炎和神经毒性的发生率均相似(P>0.05)。试验组恶心呕吐、腹泻和白细胞减少的发生率明显低于对照组(P<0.05),手足综合征的发生率显著高于对照组(P<0.05)。结论L-OPH联合卡培他滨治疗晚期直肠癌的近期疗效较好,不良反应较轻,适合临床选择应用。
Objective To study the clinical effect and security of oxaliplatin（ L-OHP） combined with capecitabine in treatment of advanced rectal carcinoma. Methods 86 patients with rectal carcinoma were chosen and divided randomly into test group and control group,in which patients were treated by LOHP combined with capecitabine and FOLFOX4,respectively. The treatment effectiveness and security were observed and compared. Results The total treatment effective rate of control group and test group were 51. 16% and 55. 81%,respectively（ 2= 0. 44,P〉0. 05）. The main adverse reactions in both groups were nausea and vomiting,diarrhea,leucopenia,thrombocytopenia,oral cavity mucocitis,hand-foot syndrome and neurotoxicity. The incidence rates of thrombocytopenia,oral cavity mucocitis and neurotoxicity were similar in two groups（ P〉0. 05）. In test group,the incidence rates of nausea and vomiting,diarrhea and leukopenic were significant lower,and the incidence rate of hand-foot syndrome was significant higher compared to those in control group（ P〈0. 05）. Conclusion L-OHP combined with capecitabine is suitable to use in clinical treatment of advanced rectal carcinoma selectively with good curative effects in the near future.
出处
《中国肿瘤临床与康复》
2015年第3期320-322,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
直肠肿瘤
药物疗法
治疗结果
Rectal neoplasms
Drug therapy
Treatment outcome
